Phase I small molecule clinical trial share vs Antibody-drug conjugate trial starts
In 2025, phase I small molecule clinical trial share worldwide was 62%; antibody-drug conjugate trial starts was 349.
Change the pair
Compare different indicators
The series
Over time
Global, annual figures, spaced by time from 2023 to 2025 . Different units, drawn on separate scales and clipped to the years both series publish; earlier history stays on each indicator’s own page. Read the values, not the heights.
Phase I small molecule clinical trial share
Unit: % · 2 observations
Antibody-drug conjugate trial starts
Unit: count · 3 observations
Shared periods
Side by side
2 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Phase I small molecule clinical trial share
Percentage of Phase I clinical trial starts that evaluate small molecule drugs.
2 observations charted in Global (of 3 annual records) · source organisations: IQVIA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
3 observations charted in Global (of 6 annual records) · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring